Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Mesothelioma, Malignant 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 11X-Rays 8Biopsy 8Temozolomide 7Phantoms, Imaging 7Radiotherapy 6Nuclear Medicine Department, Hospital 6Bevacizumab 6erdafitinib 4Surgical Procedures, Operative 4Radiation 4Nivolumab 4Carmustine 4Carboplatin 4ulixertinib 3temsirolimus 3palbociclib 3olaparib 3larotrectinib 3Vorinostat 3Sunitinib 3IL13-PE38 3Chemotherapy, Adjuvant 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioma × Etanidazole × Clear all
NCT00430079 2013-01-16

Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma

National Cancer Institute (NCI)

Phase NA Terminated
48 enrolled
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡